Outcomes of Intravitreal Bevacizumab in Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease- A Prospective Study

Purpose: To assess the effectiveness of intravitreal (IV) bevacizumab and the need for systemic immunosuppressive therapy (IMT) in choroidal neovascularization (CNV) in Vogt-Koyanagi-Harada disease (VKHD). Methods: CNV treatment consisted of three monthly IV bevacizumab injections as a loading dose;...

Full description

Saved in:

Bibliographic Details
Published in:	Ocular immunology and inflammation Vol. 29; no. 3; pp. 572 - 578
Main Authors:	Sakata, Viviane M., Morita, Celso, Lavezzo, Marcelo M., Rodriguez, Ever E. C., Abdallah, Smairah F., Pimentel, Sergio L.G., Hirata, Carlos E., Yamamoto, Joyce H.
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis 03-04-2021
Subjects:	Adult Angiogenesis Inhibitors - therapeutic use bevacizumab Bevacizumab - therapeutic use choroidal neovascularization Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Choroidal Neovascularization - physiopathology Female Fluorescein Angiography Follow-Up Studies Humans inflammation Intravitreal Injections Middle Aged Prospective Studies Subretinal Fluid Tomography, Optical Coherence Treatment Outcome Uveomeningoencephalitic Syndrome - complications Uveomeningoencephalitic Syndrome - physiopathology Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Vogt-Koyanagi-Harada bevacizumab Vogt-Koyanagi-Harada choroidal neovascularization inflammation
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Purpose: To assess the effectiveness of intravitreal (IV) bevacizumab and the need for systemic immunosuppressive therapy (IMT) in choroidal neovascularization (CNV) in Vogt-Koyanagi-Harada disease (VKHD). Methods: CNV treatment consisted of three monthly IV bevacizumab injections as a loading dose; if intra/subretinal fluid (IRF) persisted, further injections were proceeded besides increment in systemic IMT. Outcome analyses at 3, 6, and 12 months were visual acuity, central foveal thickness, macular volume, IRF, and addition of IMT. Results: Seven eyes of six patients were included. Five patients (five eyes) completed a 12-month follow-up and received 12 IV bevacizumab injections. At the 12-month follow-up, visual acuity improved in four out of five eyes (p = .0568); all eyes had decreased macular volume (p = .0431) but they still had persistent IRF; and all cases needed IMT introduction/increment. Conclusion: Intravitreal bevacizumab in association with systemic IMT was effective for CNV in VKHD. Active CNV may indicate disease of inadequate clinical control.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0927-3948 1744-5078
DOI:	10.1080/09273948.2019.1687731